Arcadia Wealth Management Inc. Acquires New Stake in Pfizer Inc. (NYSE:PFE)

Arcadia Wealth Management Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,850 shares of the biopharmaceutical company's stock, valued at approximately $527,000.

A number of other institutional investors also recently made changes to their positions in PFE. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

NYSE PFE traded up $0.29 on Tuesday, hitting $23.61. 36,119,931 shares of the company's stock were exchanged, compared to its average volume of 41,080,362. The stock has a 50-day moving average of $23.28 and a 200-day moving average of $25.12. The stock has a market cap of $134.23 billion, a price-to-earnings ratio of 16.74, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.29%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.